In a cell-type-and stimulus-dependent fashion, the early response gene immediate early gene X-1 (IEX-1) is involved in growth control and modulation of apoptosis. The present study demonstrates that, in the two acute promyelocytic leukemia (APL) cell lines NB4 and KG1, exhibiting distinct responsiveness to retinoic acids (RAs), IEX-1 expression is rapidly (30-60 min) induced by all-trans-or cis-RA and independently of other signal transduction mediators, such as TNFa, NF-jB or MAP kinases. In NB4 cells (expressing PML-RARa), this increase is transient and completely reversible, along with a cell cycle arrest, ongoing differentiation and lower sensitivity to anti-cancer-drug-induced apoptosis. In contrast, the RA-induced IEX-1 expression in KG1 cells (expressing PLZF-RARa) persists over days, along with continued cell cycle progression and increased apoptotic sensitivity. Furthermore, two functional RA-response elements in the IEX-1 promoter were identified by gel shift and luciferase reporter gene assays. IEX-1 might be a rather unique transcriptional target of the two X-RARa fusion receptors exhibiting distinct responsiveness to RAs. Following a different time course of direct transcriptional induction by PML-RARa and PLZF-RARa in NB4 and KG1 cells, respectively, IEX-1 expression may be involved in the modified actions of these receptors and the distinct phenotypes of APL cells.
Introduction
IEX-1 -also designated IER3, PRG1, DIF2 -is a widely expressed human early response gene encoding a 22-25 kDa protein [1] [2] [3] that exhibits high sequence similarity to the PRG1 and gly96 genes in the rat and mouse, 2, 4 respectively. Yet, no significant sequence similarity to any other known protein has been found, making the exact function of IEX-1 rather obscure. Meanwhile, IEX-1 gained much attention since it has been shown to be involved in the regulation of cell growth and apoptosis. 5 Several studies indicated that, in certain types of cells, expression of IEX-1 is associated with cell cycle progression and proliferation. [6] [7] [8] [9] Furthermore, IEX-1 expression modulates apoptosis as it enhances cell death induced by death ligands and by DNA-damaging conditions in some cells, [9] [10] [11] [12] [13] [14] [15] [16] but decreases activation-induced cell death in T cells. 17, 18 Thus, the effect of IEX-1 on cell growth and apoptosis seems to be greatly influenced by cell-type-specific conditions, including, ERK phosphorylation. 19 Furthermore, IEX-1 expression is under the control of a wide range of stimuli, including growth factors (ie EGF, PDGF, HGF/SF), cytokines (ie TNFa, IL6), stress factors (ie UV light, biomechanical strain), other cellular activators (ie PMA, LPS) or vitamin-D3. [1] [2] [3] [4] [6] [7] [8] 12, 13, 20, 21 Several transcription factors, such as NFkB, c-Myc, AP1, AP2, Sp1, VDR and p53, have been shown to regulate IEX-1 expression in a cell-typedependent manner. [22] [23] [24] [25] [26] [27] Gene expression and the cellular outcome hereof are particularly orchestrated by the actions of nuclear receptors, such as those for retinoic acid (RA). 28, 29 Two types of nuclear receptors for RA are known -RA receptor (RAR)-a, -b, -g , and RXR-a, -b, -g, either existing as RAR/RXR heterodimers, as RXR homodimers or as heterodimers of RXR with other nuclear receptors. RARs and RXRs interact with their cognate ligands alltrans-RA (atRA) and 9-cis-RA (cRA), respectively, causing alterations in the transcriptional activity of promoters possessing RA-responsive binding sites (RAREs) characterized by a tandem repeat sequence (A/GGGTCA) separated by one to five nucleotides. 29, 30 In this fashion, RAs essentially contribute to cellular differentiation, growth regulation, and apoptosis, and disruption of these actions is a cause of certain malignancies, such as promyelocytic leukemia (PML), where RARa is frequently fused to the PML protein or, in rare cases, to the PML-like zinc-finger protein (PLZF) protein due to chromosomal translocations (t17;15, and t17;11, respectively). Along with these genetic alterations, [31] [32] [33] myeloic progenitor cells cease differentiation and proliferate, but those PML cells expressing the PML-RARa fusion protein (ie the cell lines HL60 or NB4) are nevertheless highly RA responsive as atRA treatment induces growth arrest and cellular maturation. 34, 35 In contrast, those leukemic cells expressing the PLZF-RARa fusion protein, such as the cell line KG1, do not favorably respond to RA treatment and still remain proliferating and undifferentiated. 36, 37 Our present study on IEX-1 in RA-responsive NB4 cells (expressing PML-RARa protein) and RA-refractory KG1 cells (expressing the PLZF-RARa protein) revealed a strong inducing effect of atRA and cRA on IEX-1 expression, surprisingly, in both cell lines, mediated by two RAREs identified in the IEX-1 promoter. This induction followed distinct time kinetics along with distinct cellular responses: NB4 cells underwent growth arrest and differentiation and became less sensitive to anticancer drugs, as well, whereas KG1 cells grew faster and became more sensitive to anti-cancer drug treatment. Obviously, the transient and completely reversible IEX-1 expression is compatible with the rather differentiated and less proliferating phenotype of NB4 cells upon RA treatment, whereas the delayed and persistent increase of IEX-1 expression upon RA treatment may be related to the still proliferating and less differentiated phenotype of KG1 cells, along with increased apoptotic sensitivity.
RT-PCR
Total RNA was isolated using the RNeasy kit (Qiagen), treated with DNaseI and reverse transcribed into ss-cDNA. PCR for the detection of IEX-1 was conducted as described recently.
10 p21/Waf1, TNF receptor 1 (TNFR1) and CD11b mRNAs were analyzed as follows: 2 ml cDNA was submitted to PCR (951C, 2 min/951C, 60 s; 581C, 30 s; 721C, 30 s; for 25 cycles/721C, 10 min) using 1.5 U Taq polymerase (Gibco/BRL) and forward/reversed primers for p21/Waf1, ( 0 /5 0 -tttggagcagctgaggcagtgtct-3 0 ; Pos. 133-567; GenBank No. X55313). As internal mRNA control, b-actin was analyzed with RT-PCR amplimer primers (Clontech). PCR products were visualized by PAGE (8%) with subsequent EtBr staining, and verified by automated DNA sequencing (AbiPrism 3700) using the Big-Dye Terminator sequencing kit (Perkin-Elmer).
Gel shift assay
For gel shift assays, nuclear extracts were prepared as described previously 23 and incubated with a g 32 P-labeled oligonucleotide 5 0 -gaatgcgtgcatataactgggtcagt-3 0 (S-1) or 5 0 -cgaggcagatcacgaggtcag-3 0 (S-2) containing the putative RAR-binding sites. After 30 min incubation at room temperature, samples were separated by gel electrophoresis at 100 V and 41C. Gels were dried and exposed to X-ray Hyperfilm (Amersham; Freiburg, FRG). The binding specificity was checked by competition with a 20-fold molar excess of unlabeled oligonucleotides containing the consensus motifs RARE(DR5) 5 0 -agggtagggttcaccgaaagttcactc-3 0 and RARE(DR1) 5 0 -agcttcaggtcagaggtcagagagct-3 0 , respectively (both from Santa Cruz), or by the addition of an RXR antibody (Santa Cruz).
Cell cycle analysis and measurement of apoptosis
Cell cycle analysis was conducted by PI staining and subsequent fluorescence flow cytometry (GALAXY ARGON PLUS, Dako), as recently described. 12 Apoptosis was determined by staining with FITC-labeled annexin-V (Clontech) and subsequent fluorescence flow cytometry, as recently described. 12 Generation of expression vectors and IEX-1 promoter luciferase reporter gene constructs RARa cDNA was amplified from human liver mRNA by RT-PCR and cloned into the pCR3.1. vector. The generation of the pCMV-IEX-1 expression vector has been described recently. 12 From the cloned IEX-1 gene (GenBank Nos. X96438 and AB023051) encompassing the 5 0 flanking region À981 to À1, various shortened fragments were generated by PCR using appropriate forward primers (starting on positions À981, À750, À465 and À107). In addition, using composite primers containing restriction sites for SalI and NheI promoter fragments were generated by PCR, subcloned and religated, yielding promoter constructs lacking the positions À774 to À758 and À538 to À526, respectively. All full length, shortened and deleted promoter constructs were cloned into the pGL3 firefly luciferase reporter gene vector. The sequence of each construct was verified by automated DNA sequencing.
Dual luciferase reporter gene assays
HeLa cells transfected with pTKRL, the pGL3-promoter constructs and pCMV expression plasmids (lacZ, PML-RARa, PLZFRARa, RARa) were treated as described. Upon washing with PBS, cells were lyzed with 200 ml/well with the passive lysis buffer (Promega). Lysates were immediately frozen and thawed, followed by centrifugation for 10 min at 41C, 13 000 rpm. Supernatants were submitted to the dual luciferase assay procedure (Stop&Glo dual luciferase detection kit, Promega) using a 96-well reading plate in a Berthold luminometer. Firefly luciferase expression (pGL3-derivatives) was normalized to constitutive renilla luciferase expression (pTKRL), determined in parallel.
Cell transfections
For reporter gene assays, HeLa cells were seeded into six-well plates and transfected with the pGL3 vector or with the pGL3-IEX-1-promoter constructs (all 0.4 mg/well), together with pTKRL (0.2 mg/well) and the pCMV-lacZ, pCMV-RARa, pCMV-PML-RARa or the pCMV-PLZF-RARa vectors (all 0.4 mg/well) using the Effectene transfection reagent (Qiagen) and following the manufacturer's instructions. KG1 cells seeded in 25 cm 3 culture flasks overnight were transfected with pCMV-lacZ or pCMV-IEX-1 (5 mg/5 Â 10
Results
Effect of atRA and cRA on IEX-1 expression in NB4 and KG1 leukemic cells NB4 and KG1 leukemia cells were analyzed for the expression of the growth-and apoptosis-modulatory early response gene IEX-1, along with their distinct behavior upon treatment with RAs. As demonstrated by RT-PCR analysis using b-actin as mRNA control, IEX-1 mRNA levels rapidly increased in NB4 cells within 15-60 min after addition of 1 mM atRA, followed by a period (6 h) of sustained elevation (Figure 1a) . Then, IEX-1 mRNA levels continuously declined and returned to basal levels after 12-24 h. In KG1 cells, IEX-1 mRNA levels were increased by atRA in a slightly delayed (1-3 h) fashion, followed by a persistent elevation over 72 h ( Figure 1a) . Similarly, 1 mM cRA increased the content of IEX-1 mRNA in NB4 cells more rapidly (30-60 min) than in KG1 cells (1-3 h) and, in NB4 cells, the increasing effect of cRA on IEX-1 mRNA levels was reversible within 12-24 h, whereas this effect persisted over 72 h in KG1 cells. These distinct IEX-1 expression kinetics upon RA treatment could be verified also on the protein level by direct anti-IEX-1 immunostaining of permeabilized NB4 and KG1 cells (data not shown).
Distinct induction profiles of differentiation and growth regulation-associated genes in NB4 and KG1 cells upon atRA treatment
To address the question how the induction of IEX-1 by RA is timely related to other known target genes of RA such as p21/ Waf1, 38, 39 CD11b, 40, 41 or TNFR1, 42 RT-PCR was performed. As shown in Figure 1b , in NB4 cells p21 mRNA levels were continuously increased upon atRA stimulation, and no decline of p21/Waf1 mRNA to basal levels was seen before 48 h; then the amount of p21/Waf1 mRNA began to decrease slowly. The mRNA content of TNFR-1 or the early granulo-and monocytic maturation marker CD11b was strongly increased by atRA within 2-8 h, and persisted at high levels up to 48 h. In direct comparison, the content of IEX-1 mRNA was maximally increased in NB4 cells within a period of 1 and 6 h upon atRA administration, followed by a decrease within 12-32 h. A distinct kinetic profile was observed in KG1 cells. The level of p21/Waf1 mRNA was not significantly induced over the entire period of atRA treatment, and only a little and delayed (24-48 h) increase in the amount of CD11b mRNA was noted. In another contrast to NB4 cells, TNFR1 mRNA was already detectable at significant levels in untreated KG1 cells, and no significant increase occurred. These distinct expression levels of CD11b and TNFR-1 were also verified by FACS analysis (not shown). In direct comparison, the levels of IEX-1 mRNA were strongly increased in KG1 cells at 3-48 h upon atRA treatment.
Effects of actinomycin D, CHX and a TNFa receptor antagonist on atRA-induced IEX-1 expression in NB4 and KG1 cells
In order to investigate whether the inducing effect of atRA on IEX-1 expression depends on increased transcription, NB4 and KG1 cells were preincubated with actinomycin D (0.2 mg/ml) for 1 h. As shown by RT-PCR, the increase in IEX-1 mRNA levels in response to atRA treatment was strongly suppressed by actinomycin D (Figure 2a ). This suppressing effect was seen in both cell lines after 1 and 6 h of atRA treatment, and in KG1 cells, also after extended atRA treatment (24 h). Next, it was elucidated whether the inducing effect of atRA requires protein de novo synthesis. For this purpose, the amount of IEX-1 mRNA upon atRA adminstration was analyzed in the absence or presence of 10 mg/ml CHX. In NB4 and KG1 cells, the basal as well as the atRA-dependent increase of IEX-1 mRNA levels was significantly enhanced if CHX was present (Figure 2b) . In KG1 cells, this effect of CHX was also seen -albeit less pronouncedat longer periods of atRA treatment. Interestingly, CHX strongly increased IEX-1 mRNA levels in NB4 cells subject to atRA treatment for 24 h, a time point when both agents alone had no significant effect on IEX-1 expression. In addition, we checked whether TNFa is involved in the inducing effect of atRA on IEX-1 expression ( Figure 2b) . As shown by RT-PCR, in NB4 cells, the early increase of IEX-1 mRNA levels in response to atRA was not altered by the TNFR1 antagonist infliximab (5 mg/ml), whereas this inducing effect by atRA treatment for longer periods (6 h) was significantly reduced by the antagonist. In contrast, the 
Identification of RAREs in the IEX-1 promoter
The findings above led us to search for potential RAR-binding sites (RAREs) residing within the IEX-1 promoter. As shown in Figure 3a , two regions were found exhibiting sequence similarity with established, degenerated recognition motifs for RXR/RARa-X heterodimers. 43 These sites, composed of two 8-mer half-sites, were found at positions À778 to -757, and À540 to À524, representing a DR5-like and a DR1-like type, respectively. In order to confirm the retinoid receptor-binding activity of these sites, both sequences (S1 and S2) were used as radiolabeled probes for gel shift assays ( Figure 3b ). Using nuclear extracts from NB4 or KG1 cells treated with atRA for 1, 6, and 24 h, or not, it could be demonstrated that both probes are capable of DNA-protein complex formation in an atRAdependent fashion. In untreated NB4 cells, nuclear protein complexes with radiolabeled S1 and S2 could be identified, which were even strongly detectable in extracts from NB4 cells subject to atRA treatment for 1 h. In extracts from NB4 cells treated with atRA for 6 or 24 h, the intensities of the labeled protein complexes with both probes were significantly reduced. This decrease might reflect the atRA-induced degradation of the PML-RARa fusion protein [44] [45] [46] in this cell line. A strong DNAprotein complex was also formed with radiolabeled S-1 and S-2, if nuclear extracts from atRA-treated KG1 cells were used for gel shift assay. In contrast to NB4 cells, longer atRA treatment of KG1 cells resulted in an increased intensity of DNA-protein complex formation in gel shift assays with KG1 extracts (6, 24 h) and both radiolabeled probes. The identified DNA-protein complexes in both cell lines were further verified by the specific competing effect of a 20-fold molar excess of the unlabeled consensus sequences DR5 or DR1 and, in addition, by their disappearance in the presence of an RXRa antibody.
The IEX-1 promoter is strongly and specifically transactivated by RAR fusion proteins (X-RARs)
In order to elucidate whether the IEX-1 promoter directly mediates transcriptional activation in an RARa-and X-RARadependent fashion, respectively, various promoter constructs fused to the firefly reporter gene were generated and transfected into HeLa cells, together with expression vectors for RARa, PML-RARa and PLZF-RARa or lacZ for control. For normalization of transfection efficacy, renilla luciferase expression (via pTKRL) was measured in parallel. Analyzing the entire promoter construct (Pos. À1 to À981), it turned out that those transfectants subject to atRA treatment (1 mM, 2 h) and expressing PML-RARa or PLZF-RARa exhibit a 10-20-fold and those expressing RARa only a 3-4-fold higher firefly luciferase expression than HeLa cells transfecetd with lacZ ( Figure 4 ). In contrast, no such difference in reporter gene expression was observed in HeLa cells transfected with the minimal-promoter reporter gene construct (À1 to À107) or the empty reporter gene vector (pGL3). When analyzing a promoter construct shortened to position À1 to À750, only a 4-6-fold increase of reporter gene expression was still seen with PML-RARa or PLZF-RARa, and a nearly two-fold with RARa, compared to lacZ. A further shortened IEX-1 promoter fragment (À1 to À465) exhibited only a residual induction of reporter gene expression by PML-RARa, PLZF-RARa and RARa, which was less than two-fold in comparison with lacZ. Thus, most of the specific transactivation by X-RARs and RARa seems to be mediated by the regions between À750 and À981 and to a lesser extent between À465 and À750.
Next, promoter constructs were analyzed, containing deletions between positions À758 and À774 (DR1) or À526 and À538 (DR2). As shown in Figure 4 , the promoter construct À1 to À981 (DR1) provides only a 3-4-fold higher induction of reporter gene expression by PLZF-RARa or PML-RARa than lacz, and just a marginal induction by RARa. The construct À1 to À981 (DR2) largely retained the inducibility of reporter gene expression by PML-RARa (eight-fold), PLZF-RARa (seven-fold) and by RARa (two-fold), while the construct À1/À750 (DR2) exhibited only a maximal two-fold induction by PML-RARa or PLZF-RARa, and no significant induction by RARa compared to lacZ.
Distinct cell cycle properties and anti-cancer drug sensitivities of NB4 and KG1 cells upon atRA/cRA treatment Using PI staining and fluorescence cytometry, the effect of RAs on the cell cycle in NB4 and KG1 cells was analyzed ( Figure 5 ). Next, the sensitivity of NB4 and KG1 cells to apoptosis induced by the anti-cancer drug etoposide was investigated. As shown by the annexin V-apoptosis assay (Figure 6a ), NB4 cells (10% basal apoptosis) became slightly more sensitive to etoposide treatment (2 mM, 24 h) if preincubated with atRA and cRA for 4 h (from 67 to 81 and 80%, respectively). In contrast, the number of apoptotic cells in response to etoposide treatment became significantly less if atRA and cRA were preincubated for longer periods: 45 and 49% apoptotic cells, respectively, after 16 h. This decreased number of apoptotic cells (down to 40% or less) was also seen if atRA or cRA were preincubated for 32 h or longer. A similar decline in apoptotic sensitivity upon long-term treatment with atRA/cRA was seen with 0.5 mM etoposide (24 h 43 for aberrant RARs (depicted as RARE1 and RARE2) were identified in the IEX-1 promoter at positions À778/À757 (DR5-like) and À540/ 524 (DR1-like). The corresponding nucleotide sequences are shown below (half-sites are underlined). (b) Nuclear extracts from untreated or atRAtreated NB4 and KG1 cells were used for gel shift assay with 32 P-labeled probes S-1 (containing the DR5-like motif) and S-2 (containing the DR1-like motif). For specificity control, extracts from both cell lines subject to atRA treatment for 1 h were subject to gel shift assay in the presence of a 20-fold molar excess of an unlabeled consensus DR5 oligonucleotide, a DR1 oligonucleotide, or an unrelated control oligonucleotide (Oct1, Santa Cruz). In addition, a supershift with an anti-RXR antibody was included. Asterisks indicate the DNA/protein complex regarded as specific. All results are representative for two independent experiments.
RA-inducible IEX-1 expression
A Arlt et al apoptotic cells), but longer periods of RA treatment led to a significantly enhanced sensitivity towards etoposide (Figure 6a ). This is shown by the increased number of apoptotic cells from 42 to 460%, if atRA and cRA were preincubated for 16 h, and up to 75% apoptotic cells if atRA or cRA were preincubated for 32 h (15% basal apoptosis). After 48 h of atRA or cRA pretreatment, KG-1 cells were almost completely killed by etoposide. This increased drug sensitivity of KG1 cells upon longer RA treatment (16 and 32 h) was also seen with 0.5 mM etoposide (from 30 to 450% and 60% apoptotic cells, respectively). Over the entire period, both atRA and cRA slightly increased apoptosis if administered alone (20-25% apoptotic KG1 cells) in comparison with untreated cells (15% apoptosis).
Ectopic IEX-1 expression increases anti-cancer druginduced apoptosis of KG1 cells
In order to verify the proapototic effect of IEX-1 expression in KG1 cells, this cell line was transiently transfected with an expression vector for IEX-1 or lacZ (used as control). After overnight transfection, transfectants were treated for 24 h with etoposide (2 mM) or without, and apoptosis was determined. As shown in Figure 6b , KG1 cells transfected with lacZ exhibited a moderate basal rate of apoptosis (10-15%), and upon etoposide treatment, 450% of lacZ-transfected KG1 cells were apoptotic. A quite similar basal and anti-cancer drug-induced apoptosis was observed with untransfected KG1 cells (see above). In contrast to lacZ transfectants, KG1 cells transfected with IEX-1 (verified by Western blotting shown in Figure 6c ) were much more apoptotic in the absence (25-30%) as well as in the presence of etoposide (475% apoptotic cells). This gain in apoptosis resembles the one seen with KG1 cells subject to extended RA treatment.
Discussion
The actions of RAs on differentiation and growth of vertebrate cells involve direct effects of their cognate nuclear receptors on gene expression 28, 29 and those effects relying on positive or negative interferences with other transcription factors, such as NFkB or AP1. 42, [47] [48] [49] In the present study, we identified the stress response gene IEX-1 as a direct transcriptional target of atRA as well as cRA in two APL cell lines characterized by aberrant RARa receptors and distinct RA responsiveness. Interestingly, NB4 and KG1 cells exhibit a distinct kinetic in the RA-dependent induction of IEX-1 expression. In KG1 cells that are regarded as being almost RA nonresponsive, an even irreversible induction of IEX-1 by atRA or cRA was observed, while in NB4 cells the inducing effect of RAs on IEX-1 expression was rapidly reversed within 8 h, and only in KG1 cells the expression of IEX-1 was still elevated after longer periods (24-72 h) of RA treatment.
The finding that IEX-1 expression is directly induced by RAs not only in NB4 cells, but also in KG1 cells, was rather unexpected as it is generally accepted that the PLZF-RARa fusion protein present in KG1 cells still retains its trans-dominant repressor function, 32, 50 even during treatment with higher doses of atRA. Thus, it can be speculated that a mechanism distinct from this release from transcriptional repression accounts for the effect of atRA on IEX-1 expression in these cell lines. In fact, the RA-dependent induction of IEX-1 rather involves a direct transcriptional activation of the IEX-1 promoter by the X-RARa fusion proteins, as shown by luciferase-reporter gene assays. In a similar way, other directly induced target genes of both PLZF-RARa and PML-RARa have been identified quite recently. 51 Nevertheless, the timely distinct RA-induced expression pattern of IEX-1 was in line with a distinct phenotype of NB4 and KG1 cells upon RA treatment. In contrast to KG1 cells that persisted in their highly proliferating and undifferentiated phenotype, NB4 cells turned to a less proliferating phenotype along with the onset of differentiation, as indicated by a continuously increased p21/Waf1 and CD11b expression, respectively. As an important consequence, KG1 cells became much more sensitive to anti-cancer-drug-induced apoptosis (ie by etoposide or doxorubicin) compared to NB4 cells, an effect that might involve the still elevated IEX-1 expression. In support of this assumption, we could show that ectopic expression of IEX-1 in transiently transfected KG1 cells leads to a similar sensitization towards apoptosis as the prolonged RA treatment of this cell line and its persistent induction of IEX-1 expression. Such a proapoptotic action of IEX-1 in the presence of additional cell death inducing stimuli has been also reported for several other cell types more recently. [12] [13] [14] [15] [16] In addition, KG1 cells did not undergo a cell cycle arrest as NB4 cells, which is also in line with the implication of IEX-1 in cell cycle progression. 9 In contrast to recent reports that described either downregulation of IEX-1 expression by other types of nuclear receptors, such as the VD3R, 20 or rather its synergistic upregulation with atRA and TNFa, 47 we observed a direct inducing effect of RAs on IEX-1 transcription in NB4 and KG1 cells, mediated by two newly discovered degenerated but functional RAREs (DR5-like at position À757/À778, and DR1-like at position À540/À524) in the IEX-1 promoter. Data from luciferase reporter gene assays underscored the particular importance of the DR5-like site for the inducibility of the IEX-1 promoter by PML-RARa and PLZF-RARa, whereas the DR1-like site contributes to X-RARa and RARa-dependent transactivation to a lesser extent. The slight residual activity of the IEX-1 promoter lacking these two sites with respect to X-RARainduced transcription might be due to rather indirect effects related to other binding elements.
The identity of IEX-1 as a direct transcriptional target of the XRARs was also confirmed by the finding that the rapid RAinduced increase of IEX-1 mRNA levels in both cell lines is suppressed by the transcriptional inhibitor actinomycin D. In addition, the RA-dependent increase of IEX-1 mRNA levels was not affected by MEK1 and NFkB inhibitors (results not shown), suggesting that these activities are not required for the inducing effect of the RAs on IEX-1 transcription. In this respect, the TNF-R(I) antagonist infliximab was also ineffective over the entire period (24 h) of RA treatment in KG1 cells, suggesting that TNFa is not involved in RA-induced IEX-1 expression. In contrast, in NB4 cells the delayed (3-6 h) increase of IEX-1 expression was blocked by the antagonist, suggesting that the delayed but not the early induction of IEX-1 expression by RAs requires TNFa in this cell line. 47 Furthermore, the inducing effect of atRA in both cell lines does not require de novo protein synthesis, that is, of other transcription factors or any other inducing mediator, and therefore relies on the direct action of the RA receptors. The fact that the IEX-1 transcription is rather superinduced by the protein synthesis inhibitor CHX reflects an inverse relation of IEX-1 mRNA stability and protein translation, 1,2 as it has been reported for several other short-lived mRNAs containing an AUrich element in the 3 0 untranslated region. 52, 53 The finding that in NB4 cells CHX strongly increased the atRA-induced IEX-1 mRNA expression even at later periods (24 h), when atRA alone was without effect, further suggests that a newly synthesized inhibitory component might be responsible for the strongly reversible course of IEX-1 expression in this cell line. Consequently, in KG1 cells the direct effect of atRA on IEX-1 expression is much more durable, implying a greater stability of the inducing PLZF-RARa receptor, while in NB4 cells the induction of IEX-1 expression is reversed by the RA-induced destruction of the inducing PML-RARa receptor and the appearance of repressive proteins. Favoring this view, the proteasome inhibitor MG132 increased the inducing effect of atRA on IEX-1 expression in NB4 cells, reflecting the reduced ligand-dependent degradation of PML-RARa and RARa [44] [45] [46] that was seen in this cell line, but not in KG1 cells where PLZF-RARa and RARa remained stable (result not shown).
The finding that IEX-1 is a target gene of RAs in two APL cell lines with distinct RARa-X aberrations is intriguing as it raises the question how IEX-1 may be implicated in the phenotypical changes of APL cells upon atRA treatment. This is of particular importance regarding the outcome of APL treatment with atRA in combination with chemotherapy. 54 ,55 KG1 cells were classified as being nonresponsive to atRA in terms of their lacking cellular maturation and continued proliferation, but this would not apply to the apoptotic behavior as KG1 cells become 
Figure 5
Effect of atRA and cRA on the cell cycle in NB4 and KG1 cells. Propidium iodide staining was performed with NB4 and KG1 cells subject to treatment with 1 mM atRA or cRA for the indicated periods. Cell cycle distribution was determined by FACS analysis. The data express the mean7s.d. of four independent analyses. more sensitive to apoptosis if treated with atRA for longer periods. This increased sensitivity may be related to the persistent elevation of IEX-1 expression and its profound apoptosis-sensitizing potential. [12] [13] [14] [15] [16] Conversely, NB4 cells turn to a more differentiated and less proliferative phenotype, but exhibit a reduced sensitivity towards drug-induced apoptosis upon longer periods of RA treatment. 54 Here, the temporary increase of IEX-1 expression is obviously not sufficient for the development of a still proliferating and chemosensitive phenotype. Instead, the ultimately reduced presence of IEX-1 may be related to the onset of differentiation, as it has been reported recently for monocytes. 3 Thus, for the therapeutic rationale, one has to take into account that the obviously lacking benefit of atRA treatment in RA-insensitive APL cells does not necessarily apply to anti-cancer-drug sensitivity. As we have shown here, IEX-1 expression may relate to a more sensitive phenotype of APL cells against chemotherapy that could be gained by atRA treatment and this may add to the benefit of combined RA/ chemotherapy. 
Apoptotic cells (%)
w
